Shield Therapeutics has announced that the Korean Ministry of Food and Drug Safety (MFDS) has granted regulatory approval for ACCRUFeR® (Ferric Maltol) in the Republic of Korea (South Korea). As potential approval in South Korea had been anticipated by the end of 2025, today’s news comes within the existing expected timeframes and heralds another significant step forward in the commercial development of ACCRUFeR. As a result, Shield is eligible to receive payments upon the first sale, as well as ....
